Amarin Corp Plc (AMRN)

[alm2]

Hamoa’s point is that it is uneconomic for a generic - the first generic - to launch - followed 6 months later by two other generics -and maybe more ?? Amarin selling V as cheap as generics can - for if generic can profit from a generic version so to may Amarin ?
Is there any profit to be had by launching now ?- even though you may be the first to launch (only a six month gain) - that is the question for Teva. And then if Teva don’t launch do Hikma and Dr R - ?

Or do they all wait until Amarin has developed a big fat market for them to try carve up ?

It’s an interesting question ...
another year or two of USA market without completion will help Amarin as to Europe/ Row

Generics want to make money not loose it ... so they have much to consider perhaps
Alm